Abstract:
Aim: Bursectomy, mainly defined as a complete dissection of the peritoneal lining covering the anterior plane of the transverse
mesocolon and the pancreas with an omentectomy during gastrectomy, has been performed for the serosa-positive gastric cancers.
Recently, some researchers have interrogated whether bursectomy for gastric cancer is essential from a surgical point of view, thus,
we aimed to investigate the short-term surgical and early-stage clinicopathological outcomes of bursectomy in the treatment of
advanced gastric cancer patients by a single center study and retrospective controlled trial.
Material and Methods: From January 2016 to December 2017, retrospective findings of selected 100 gastric cancer patients in
advanced tumor stages and underwent D2 radical gastrectomy were grouped and analyzed in terms of bursectomy performed or not
in Bakirkoy Dr. Sadi Konuk Training and Research Hospital.
Results: In conclusion, 50 patients were in bursectomy (B) group and 50 patients in non-bursectomy (NB) group. Clinical features
(age, gender, and gastrectomy pattern and tumor location) of both groups showed no statistically significant difference. Postoperative
mortality rate were also similar of both groups (4%). All other post-operative complications were not significantly distinctive for two
groups.
Conclusions: Bursectomy may increase the surgical duration of D2 gastrectomy and but not early-stage outcomes and postoperative complications. Experienced surgeons can perform the procedure safely. However, long-term, large sample sized, and
high-quality randomized controlled trials are needed for the survival benefits of bursectomy.
